AVTX
Avalo Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 51 | +13 | 31.74M | $586.58M | +19 | −6 |
| Q1 2026 | 38 | +3 | 12.35M | $184.22M | +7 | −4 |
| Q4 2025 | 35 | +2 | 8.20M | $148.88M | +2 | — |
| Q3 2025 | 13 | +7 | 3.14M | $39.85M | +7 | — |
| Q2 2025 | 4 | +1 | 446.19K | $2.23M | +1 | — |
| Q1 2025 | 1 | -1 | 107.81K | $864,389 | — | −1 |
| Q4 2024 | 2 | +1 | 120.18K | $892,907 | +1 | — |
| Q3 2024 | 1 | +1 | 10.11K | $95,649 | +1 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 166.94K | — | $833,036 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | BlackRock ✦ (passive) | 155.90K | — | $777,936 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | Geode Capital Management ✦ (passive) | 110.46K | +2.5% | $551,613 | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Two Sigma Investments ✦ | 12.89K | New | $64,316 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $64,316 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 96 holders, 30.91M shares, $428.51M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 12.39K sh · $202,437
Officer · 10.19K sh · $179,457
Officer · 679 sh · $13,580
Officer · 31.03K sh · $622,324
Officer · 37.95K sh · $753,333
Officer · 3.75K sh · $74,762
Officer · 1.00K sh · $20,000
Officer · 2.65K sh · $52,012
Officer · 679 sh · $13,580
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology